Influenza pandemic preparedness in France: Modelling the impact of interventions

Journal of Epidemiology and Community Health

Volumn 60, Issue 5, 2006, Pages 399-404

  Doyle, Aoife ^a,b   Bonmarin, Isabelle ^b   Lévy Bruhl, Daniel ^b   Le Strat, Yann ^b   Desenclos, Jean Claude ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR;

HEALTH POLICY; INFLUENZA; MONTE CARLO ANALYSIS; PROBABILITY; SIMULATION; VACCINATION;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FRANCE; HEALTH CARE PLANNING; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; INTERVENTION STUDY; MEDICAL LITERATURE; MONTE CARLO METHOD; NEWBORN; PROPHYLAXIS; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMPUTER SIMULATION; DISEASE OUTBREAKS; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MODELS, THEORETICAL; OSELTAMIVIR;

EURASIA; EUROPE; FRANCE; WESTERN EUROPE;

EID: 33646249926     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2005.034082     Document Type: Article

References (27)

1. World Health Organisation. WHO consultation on priority public health interventions before and during an influenza pandemic. Geneva, WHO, 2004 http://www.who.int/csr/disease/avian_influenza/consultation/en/ (accessed 13 Jan 2005).
2. World Health Organisation. WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Geneva, WHO, 2004 http:// www.who.inf/csr/resources/publications/influenza/ WHO_CDS_CSR_RMD_2004_8/en/ (accessed 13 Jan 2005).
3. World Health Organisation. Influenza pandemic preparedness plan. The role of WHO and guidelines for national or regional planning. Geneva: WHO, 1999, http://www.who.int/csr/resources/publications/influenza/ WHO_CDS_CSR_EDC_99_1/ en/ (accessed 13 Jan 2005).
4. The National Influenza Pandemic Planning Committee. A model plan for influenza pandemic preparedness. Version 5.2, 2002. http://www.dohc.ie/ publications/pdf/panflu.pdf
5. Fock R, Bergmann H, Bussmann H, et al. Influenza pandemic: preparedness planning in Germany. Euro Surveill 2002;7:1-5.
6. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-71.
7. van Genugten ML, Heijnen ML, Jager JC. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerg Infect Dis 2003;9:531-8.
8. Department of Health and Ageing, Commonwealth of Australia. Australian management plan for pandemic influenza, June 2005. http:// www.health.gov.au/ intenet/WCMS/publishing.nsf/Contents/phd-pandemic-plan.htm
9. Longini IM Jr, Halloran ME, Nizam A, et al. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004;159:623-33.
10. Rezza G. Avian influenza: a human pandemic threat? J Epidemiol Community Health 2004;58:807-8.
11. Moscona A. Oseltamivir-resistant influenza? Lancet 2004;364:733-4.
12. Institute de veille sanitaire. Plan governemental de prévention et de lutte "Pandémie grip pale". No/700/SGDN/PSE/PPS. Fiches techniques. Saint-Maurice: Institute de Veille Sanitaire, 2006. http:www.sante.gouv.fr/htm/ dossiers/grippe_pandemie/sommaire.htm
13. L'Assurance Maladie des salaries-sécurité sociale. Vaccination antigrippale: campagne d'information 2003. Paris: 2003, http://www.ameli.fr/pdf/ 1044.pdf (accessed 4 May 2005).
14. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003;21:1762-8.
15. Hannoun C. Spanish flu (1918-1919): an accident in history? (In French). Virologie 2002;6:S83-90.
16. Doyle A, Bonmarin I, Levy-Bruhl D, et al. Préparation d la lutte contre une pandémie grippale: estimation de l'impact d'une pandémie grippale et analyse de strategies. Saint-Maurice: Institute de Veille Sanitaire, 2005. http://www.sante.gouv.fr.htm/dossiers/grippe_pandemie/ rapport_pandemie_gripp
17. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235.
18. Hayden FG, Belshe R, Vilianueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189:440-9.
19. The Roche group. Factsheet Tamiflu. Basle, 1 Feb, 2006. http:// svww.roche.com/med_motamiflu05e.pdf
20. Couch RB. Influenza: prospects for control. Ann Intern Med 2000;133:992-8.
21. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003;36:1552-61.
22. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
23. Influenza vaccines. Wkly Epidemiol Rec 2002;77:230-9.
24. Kawai N, Ikematsu H, Iwaki N, et al. A prospective, internet-based study of the effectiveness and safely of influenza vaccination in the 2001-2002 influenza season. Vaccine 2003;21:4507-13.
25. von Genugten ML, Heijnen ML. The expected number of hospitalisations and beds needed due to pandemic influenza on a regional level in the Netherlands. Virus Res 2004;103:17-23.
26. Medema JK, Zoellner YF, Ryan J, et al. Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply. Virus Res 2004;103:9-15.
27. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-65.